Relay Therapeutics, Inc. (RLAY) - Q3 2024 10-Q Summary
Business Context and Reporting Period
Relay Therapeutics, Inc. is a clinical-stage precision medicine company utilizing its Dynamo® platform to discover small molecule therapeutics for oncology and genetic diseases. This report covers the quarterly period ended September 30, 2024. The company has no products approved for commercial sale and has not generated revenue from product sales.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $0 | $25.2 million | $10.0 million | $25.5 million |
| Net Loss | $(88.1) million | $(65.7) million | $(261.7) million | $(258.5) million |
| Net Loss Per Share | $(0.63) | $(0.54) | $(1.94) | $(2.12) |
| R&D Expenses | $76.6 million | $81.5 million | $251.0 million | $252.5 million |
| G&A Expenses | $19.8 million | $18.5 million | $59.7 million | $58.2 million |
| Cash & Investments | $839.6 million (as of Sept 30, 2024) | |||
| Accumulated Deficit | $1.66 billion (as of Sept 30, 2024) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to $0 in Q3 2024 from $25.2 million in Q3 2023. This decrease is primarily due to the recognition of $25.0 million in variable consideration from the Genentech collaboration in the prior year, which was not repeated in the current quarter. YTD revenue was $10.0 million, driven by a milestone payment.
- Genentech Termination: On July 11, 2024, Genentech notified Relay of its intent to terminate the collaboration agreement for migoprotafib (RLY-1971) without cause. The termination becomes effective 180 days after notice. No further milestones or payments are expected after the termination date.
- Capital Raising: In September 2024, the company completed a follow-on public offering of 32.9 million shares at $7.00 per share, raising net proceeds of approximately $218.2 million. In January 2024, a private placement raised $29.8 million.
- Contingent Liability Resolution: The contingent consideration liability related to the ZebiAI acquisition was reduced to $0 during the nine months ended September 30, 2024, resulting in a non-cash gain of $13.2 million in the YTD period.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash, cash equivalents, and investments ($839.6 million) will fund operations into the second half of 2027. The company expects to continue incurring significant operating losses for the foreseeable future.
- Clinical Updates:
- RLY-2608 (PI3Kα inhibitor): Interim data from the ReDiscover Trial showed a median progression-free survival of 9.2 months and an objective response rate of 33% (53% in kinase mutation patients) in HR+/HER2- metastatic breast cancer. The company plans to initiate a triplet combination arm with Pfizer's atirmociclib.
- Lirafugratinib (RLY-4008): The company plans to seek a global commercialization partner for this FGFR2 inhibitor to maintain focus on the rest of its portfolio. Enrollment in the ReFocus Trial has been closed to allow data maturation.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the potential inability to secure a commercialization partner for lirafugratinib, reliance on third-party manufacturers and CROs, and the need for substantial additional funding to sustain operations and development.
Investor Verification Checklist
- Verify the timeline and financial impact of the Genentech collaboration termination and the cessation of future milestone payments.
- Confirm the status of the search for a global commercialization partner for lirafugratinib (RLY-4008).
- Review the detailed interim clinical data for RLY-2608, specifically regarding safety profiles and efficacy in specific mutation subgroups.
- Assess the company's burn rate relative to the $839.6 million cash position to validate the "second half of 2027" runway estimate.
- Monitor the progress of the new "at-the-market" sales agreement with TD Securities and any future equity dilution.